SX-682 + enzalutamide

SX-682 + enzalutamide is an experimental drug combination currently being evaluated for metastatic castration-resistant prostate cancer (mCRPC) in patients who have failed abiraterone therapy. SX-682 is an oral, allosteric small-molecule inhibitor of the chemokine receptors CXCR1 and CXCR2, which are central regulators of the tumor microenvironment, controlling tumor cell metastasis, recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs), and angiogenesis. By inhibiting MDSC trafficking, SX-682 aims to suppress tumor-induced immune suppression and potentially enhance antitumor immune responses. Enzalutamide is a potent oral androgen receptor inhibitor approved for the treatment of castration-resistant prostate cancer; it blocks androgen receptor signaling, a pathway critical for prostate cancer progression. The SX-682 + enzalutamide combination is designed to synergistically target both immune suppression (via the CXCR1/2 axis) and tumor cell proliferation (via androgen receptor blockade)[1][2][3][4][5][7].